Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Genelux Corp (GNLX)

Genelux Corp (GNLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer GlobeNewswire - Tue Jun 30, 7:00AM CDT

- Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from Phase 2 VIRO-15 trial - - Data demonstrate Olvi-Vec–mediated...

GNLX : 3.03 (+1.68%)
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates GlobeNewswire - Thu May 7, 3:15PM CDT

-- Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Systemic lung cancer programs advancing with additional updates expected...

GNLX : 3.03 (+1.68%)
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates GlobeNewswire - Thu Mar 19, 3:15PM CDT

-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses...

GNLX : 3.03 (+1.68%)
Genelux Corporation to Participate in Upcoming Conferences GlobeNewswire - Wed Feb 18, 7:00AM CST

WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the Company will participate in...

GNLX : 3.03 (+1.68%)
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners GlobeNewswire - Mon Jan 12, 3:00PM CST

WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...

GNLX : 3.03 (+1.68%)
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock GlobeNewswire - Thu Jan 8, 8:13AM CST

WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten...

GNLX : 3.03 (+1.68%)
Genelux Corporation Announces Proposed Public Offering of Common Stock GlobeNewswire - Wed Jan 7, 3:01PM CST

WESTLAKE VILLAGE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced a...

GNLX : 3.03 (+1.68%)
Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials GlobeNewswire - Mon Jan 5, 7:00AM CST

-- Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed immunochemotherapy across ongoing SCLC and NSCLC trials; enrollment...

GNLX : 3.03 (+1.68%)
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer GlobeNewswire - Fri Jan 2, 7:00AM CST

WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) --   Genelux Corporation ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten,...

GNLX : 3.03 (+1.68%)
Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference GlobeNewswire - Wed Nov 26, 2025

WESTLAKE VILLAGE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation ( NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...

GNLX : 3.03 (+1.68%)

Barchart Exclusives

Nvidia Stock Hasn’t Been This Cheap Since Before 2019. How to Play NVDA Stock Here. Barchart - 51 minutes ago
Nvidia's valuation has fallen to its lowest level since 2019, even as Wall Street continues to see strong upside. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.